目录产品 » CD96/TACTILE mFc Chimera, Human
Manual
SDS
COAs

CD96/TACTILE mFc Chimera, Human

The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
￥3500
Z04238-100

产品简介
Species Human
Protein Construction
CD96/TACTILE (Val22-Met503)
Accession # P40200-2		 mFc (IgG1)
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized CD96/TACTILE mFc Chimera, Human at 5μg/ml (100μl/Well) on the plate can bind Human CD155, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 79.8 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 120-160 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
Synonyms CD96 molecule; CD96; DKFZp667E2122; TACTILE
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.